The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ACLARIS THERAPEUTICS INC | COM | 00461U105 | 12,648 | 1,954,932 | SH | SOLE | 1,954,932 | 0 | 0 | ||
ALIGOS THERAPEUTICS INC | COM | 01626L105 | 11,196 | 404,906 | SH | SOLE | 404,906 | 0 | 0 | ||
ALTIMMUNE INC | COM | 02155H200 | 50,760 | 4,500,000 | SH | SOLE | 4,500,000 | 0 | 0 | ||
ATHIRA PHARMA INC | COM | 04746L104 | 57,938 | 1,691,623 | SH | SOLE | 1,691,623 | 0 | 0 | ||
BIOATLA INC | COM | 09077B104 | 3,401 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
BCTG ACQUISITION CORP | COM | 05492W103 | 5,720 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
CELLDEX THERAPEUTICS INC | COM | 15117B202 | 14,016 | 800,000 | SH | SOLE | 800,000 | 0 | 0 | ||
CONSTELLATION PHARMACEUTICAL | COM | 210373106 | 115,686 | 4,016,873 | SH | SOLE | 4,016,873 | 0 | 0 | ||
COGENT BIOSCIENCES INC | COM | 19240Q201 | 12,227 | 1,088,817 | SH | SOLE | 1,088,817 | 0 | 0 | ||
FIVE PRIME THERAPEUTICS INC | COM | 33830X104 | 4,170 | 245,122 | SH | SOLE | 245,122 | 0 | 0 | ||
GALERA THERAPEUTICS INC | COM | 36338D108 | 9,390 | 917,860 | SH | SOLE | 917,860 | 0 | 0 | ||
KINNATE BIOPHARMA INC | COM | 49705R105 | 58,596 | 1,473,014 | SH | SOLE | 1,473,014 | 0 | 0 | ||
KEROS THERAPEUTICS INC | COM | 492327101 | 47,424 | 672,306 | SH | SOLE | 672,306 | 0 | 0 | ||
KURA ONCOLOGY INC | COM | 50127T109 | 18,780 | 575,000 | SH | SOLE | 575,000 | 0 | 0 | ||
MARINUS PHARMACEUTICALS INC | COM | 56854Q200 | 31,585 | 2,588,941 | SH | SOLE | 2,588,941 | 0 | 0 | ||
METACRINE INC | COM | 59101E103 | 5,452 | 693,673 | SH | SOLE | 693,673 | 0 | 0 | ||
OLEMA PHARMACEUTICALS INC | COM | 68062P106 | 73,860 | 1,536,193 | SH | SOLE | 1,536,193 | 0 | 0 | ||
RELMADA THERAPEUTICS INC | COM | 75955J402 | 21,437 | 668,440 | SH | SOLE | 668,440 | 0 | 0 | ||
SILVERBACK THERAPEUTICS INC | COM | 82835W108 | 6,951 | 150,000 | SH | SOLE | 150,000 | 0 | 0 | ||
SYNDAX PHARMACEUTICALS INC | COM | 87164F105 | 24,803 | 1,115,255 | SH | SOLE | 1,115,255 | 0 | 0 | ||
SURFACE ONCOLOGY INC | COM | 86877M209 | 13,332 | 1,442,895 | SH | SOLE | 1,442,895 | 0 | 0 | ||
TRILLIUM THERAPEUTICS INC | COM | 89620X506 | 59,428 | 4,040,000 | SH | SOLE | 4,040,000 | 0 | 0 | ||
TAYSHA GENE THERAPIES INC | COM SHS | 877619106 | 2,866 | 107,982 | SH | SOLE | 107,982 | 0 | 0 | ||
VIRIDIAN THERAPEUTICS INC | COM | 92790C104 | 321 | 19,495 | SH | SOLE | 19,495 | 0 | 0 | ||
VISTAGEN THERAPEUTICS INC | COM | 92840H202 | 18,158 | 9,360,000 | SH | SOLE | 9,360,000 | 0 | 0 |